[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639358":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":17,"centralContacts":30,"locations":36,"responsibleParty":50,"collaborators":55,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":17,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":17,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":82,"whyStopped":17,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"King Abdullah University Hospital","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"salbutamol group for diabetic patients","EXPERIMENTAL","for diabetic patients",[13],"Drug: Salbutamol (Ventolin®)",{"label":15,"type":16,"description":17,"interventionNames":17},"no intervention for diabetic","NO_INTERVENTION",null,{"label":19,"type":10,"description":20,"interventionNames":21},"salbutamol group for non-diabetic patients","for non-diabetic patients",[13],{"label":23,"type":16,"description":20,"interventionNames":17},"no intervention for non-diabetic patients",[25],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":17},"DRUG","Salbutamol (Ventolin®)","-4 puffs of salbutamol (each puff = 100 µg, total dose 200-400 µg)",[9,19],[31],{"name":32,"role":33,"phone":34,"phoneExt":17,"email":35},"Diab Bani Hani Bani Hani","CONTACT","+962798661232","dabanihani@just.edu.jo",[37],{"facility":5,"status":17,"city":38,"state":17,"zip":17,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Irbid","Jordan","JO",{"type":42,"coordinates":43},"Point",[44,45],35.85,32.55556,{"lat":45,"lon":44},[48],{"name":49,"role":33,"phone":17,"phoneExt":17,"email":17},"Principal Investigator Principal Investigator",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":54,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Diab Bani Hani","Assistant Professor of Anesthesia","Jordan University of Science and Technology",[56],{"name":54,"class":6},"100639358","early-phase-1-the-role-intraoperative-salbutamol-inhaler-in-preventing-atelectasis-100639358",false,"NCT07591558","The Role Intraoperative Salbutamol Inhaler in Preventing Atelectasis","The Role Intraoperative Salbutamol Inhaler Usage as Part of Intraoperative Regimen in Preventing Atelectasis Following Thoracic, Abdominal and Spinal Surgery in Diabetics Population","Inclusion Criteria:\n\n* The study will include patients aged 18-70 years\n* American Society of Anesthesiologists (ASA) physical status of I or II\n* Will undergo thoracic, abdominal or spinal surgery\n\nExclusion Criteria:\n\n* cardiac conditions other than hypertension like arrhythmia\n* previous cardiac surgeries and valvular heart diseases","ALL","18 Years","70 Years",{"count":68,"type":69},80,"ESTIMATED","INTERVENTIONAL",[72],"EARLY_PHASE1","Atelectasis is considered a common complication in the perioperative period, especially following surgeries under general anesthesia. Postoperative atelectasis could occur anytime during the perioperative period from intraoperative period to 24 hours postoperative and contribute to a variety of other complications, including hypoxemia and pneumonia. In the literature, several methods were utilized to combat this phenomenon, therefore, we investigate the role of intraoperative salbutamol in reducing the incidence of atelectasis. It is well known that salbutamol could be an adjunctive bronchodilator medication used in the intraoperative anesthetic regimens.",[75,76],"Atelectases, Postoperative Pulmonary","Diabete Mellitus",[78,79,80,81],"atelectasis","salbutamol","pulmonary","bronchodilator","NOT_YET_RECRUITING","2026-05-11",{"date":85,"type":86},"2026-05-15","ACTUAL",{"date":88,"type":69},"2026-06",{"date":90,"type":69},"2026-12",{"name":5,"class":6},1]